# Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation

> **NCT05627518** · PHASE1 · COMPLETED · sponsor: **Cinclus Pharma Holding AB** · enrollment: 67 (actual)

## Conditions studied

- Safety
- Bioavailability
- Pharmacokinetics

## Interventions

- **DRUG:** Linaprazan glurate

## Key facts

- **NCT ID:** NCT05627518
- **Lead sponsor:** Cinclus Pharma Holding AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-15
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-01-03
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05627518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05627518, "Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05627518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*